Background Dyslipidaemia is a potential independent The aim of this study was to investigate dyslipidaemia, with ischemic stroke in a Chinese hospital. risk factor for cerebrovascular disease in patients with diabetes...Background Dyslipidaemia is a potential independent The aim of this study was to investigate dyslipidaemia, with ischemic stroke in a Chinese hospital. risk factor for cerebrovascular disease in patients with diabetes. treatment and control of dyslipidaemia among diabetic patients Methods A total of 1046 type 2 diabetic patients were assigned to diabetes with （n=-522） and diabetes without stroke groups. The two groups were matched by gender, age and diabetes duration. Lipid and lipoprotein profile were measured. Serum level and control of lipids were assessed and classified according to American Diabetes Association （ADA） guidelines and an intensified low density lipoprotein-cholesterol （LDL-C） target recommended in Chinese dyslipidaemia control criteria. Results Diabetic patients suffering stroke displayed not only poorly-controlled lipid and lipoprotein profiles, including the significantly lower proportion of patients achieving intensified LDL-C target of 〈2.07 mmol/L （80 mg/dl）, and high density lipoprotein-cholesterol （HDL-C） target （14.4% vs 21.0%, P=0.005; 45.8% vs 51.9%, P=0.048 respectively）, but also less adherence to therapy prescribed for dyslipidaemia （30.8% vs 41.0%, P=0.001）, when compared with diabetic patients without stroke. For the diabetic women with stroke, situation of dyslipidaemia was worse, with significantly lower serum level of HDL-C and apoA1, higher LDL-C level and higher ratio of apoB/apoA1 when compared with diabetic counterparts without stroke. Conclusions Many diabetic patients with ischemic stroke remain uncontrolled for dyslipidaemia. Intensified LDL-C and overall lipid lowering clinical goals are potential precautions taken against ischemic stroke among diabetic patients in China.展开更多
目的证实无论患者是否有血糖升高,非高密度脂蛋白胆固醇(non-high density lipoprotein-cholesterol,non-HDL-C)都是不弱于低密度脂蛋白胆固醇(low density lipoprotein-cholesterol,LDL-C)的评估血脂异常患者患者心血管病风险和降脂治...目的证实无论患者是否有血糖升高,非高密度脂蛋白胆固醇(non-high density lipoprotein-cholesterol,non-HDL-C)都是不弱于低密度脂蛋白胆固醇(low density lipoprotein-cholesterol,LDL-C)的评估血脂异常患者患者心血管病风险和降脂治疗疗效的有效临床指标。方法选取2007年首都医科大学附属北京同仁医院内分泌科大规模临床调查患者6 341例,检测总胆固醇(total cholesterol,TC)、高密度脂蛋白胆固醇(high density lipoprotein-cholesterol,LDL-C)、三酰甘油(triglyceride,TG),并且计算non-HDL-C(non-HDL-C等于TC-HDL-C)。根据空腹血糖高低分为血糖正常组和血糖升高组,比较两组中血脂异常患者的各项血脂指标;以non-HDL-C为纵轴,分别以LDL-C和TG为横轴作散点图。结果血糖升高组的TC、LDL-C、HDL-C、TG、non-HDL-C较血糖正常组均明显升高。作non-HDL-C与LDL-C和TG相关性的散点图并作趋势拟合线后,发现non-HDL-C与LDL-C、TG均呈线性正相关。结论 non-HDL-C是一项评估血脂异常患者心血管病风险和降脂治疗疗效的有效临床指标。展开更多
目的评价血脂康胶囊治疗血脂异常的临床效果和安全性。方法计算机检索PubMed、Web of Science核心集、中国知网、万方、维普等数据库中血脂康治疗血脂异常随机对照试验,检索时间截至2018年6月。采用Revman5.3软件进行Meta分析,系统评价...目的评价血脂康胶囊治疗血脂异常的临床效果和安全性。方法计算机检索PubMed、Web of Science核心集、中国知网、万方、维普等数据库中血脂康治疗血脂异常随机对照试验,检索时间截至2018年6月。采用Revman5.3软件进行Meta分析,系统评价血脂康对总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)的影响。结果共纳入25项随机对照试验、7875例患者。Meta分析显示:与空白对照组比较,血脂康明显降低TC(WMD=-1.05,95%CI:-1.40,-0.70,P<0.01)和LDL-C(WMD=-0.76,95%CI:-0.94,-0.58,P<0.01)水平,升高LDL-C水平(WMD=0.17,95%CI:0.08,0.27,P<0.01)。与他汀对照组比较,血脂康能升高HDL-C水平(WMD=0.17,95%CI:0.04,0.30,P<0.05),虽然也降低TC和LDL-C水平,但差异无统计学意义(P>0.05)。与对照组比较,血脂康不良反应/主要心脑血管事件发生率明显降低(WMD=0.55,95%CI:0.47,0.64,P<0.01)。结论血脂康能够有效、全面地调脂,并且不良事件发生率低。展开更多
Aim： To evaluate the impact of age and gender on lipid and lipoprotein profiles and the burden of dyslipidemia in a cohort of healthy Chinese Singaporean. Methods： A total of 1 775 healthy Chinese, 536 men and 1 239...Aim： To evaluate the impact of age and gender on lipid and lipoprotein profiles and the burden of dyslipidemia in a cohort of healthy Chinese Singaporean. Methods： A total of 1 775 healthy Chinese, 536 men and 1 239 women aged between 30 and 70 years old were involved in the present study. Results： Gender differences in all lipid and lipoprotein levels were clearly evident. Singaporean Chinese men have significantly higher levels of total cholesterol （TC）, triglyceride （TG）, low density lipoprotein-cholesterol （LDL-C） and total cholesterol/high density lipoprotein-cholesterol （TC/HDL-C）, and lower levels of HDL-C than women. Although lipid and lipoprotein levels in men did not change in the different age groups, those in women, especially TC, LDL-C and TC/HDL-C, were significantly higher in older women （〉 50 years old） than corresponding levels in younger women （30-46 years old）. Furthermore, TG was significantly correlated with lipids and lipoproteins differently in men and women. If 100 mg/dL of LDL-C were to be adopted as the therapeutic cut-off level, then the burden of care will be huge as approximately 90% of both Chinese men and women have LDL-C greater than 100 mg/dL. Condusion： In light of the findings of the present study, we suggest that preventive measures to promote the reduction in risk of coronary heart disease （CHD） must address the high proportion of men and women with high LDL-C, and that these measures should take into account both the gender and age factors. For men, reduction of high cholesterol must start early in life, whereas for women, steps must be taken earlier to mitigate the anticipated sharp increase in risk, especially after menopause.展开更多
动脉粥样硬化(atherosclerosis, AS)是一种复杂的慢性进行性动脉疾病,被视为全球死亡的重要原因。高水平的血浆低密度脂蛋白胆固醇(low density lipoprotein-cholesterol, LDL-C)是AS发生和发展的关键危险因素。血浆中循环的前蛋白转化...动脉粥样硬化(atherosclerosis, AS)是一种复杂的慢性进行性动脉疾病,被视为全球死亡的重要原因。高水平的血浆低密度脂蛋白胆固醇(low density lipoprotein-cholesterol, LDL-C)是AS发生和发展的关键危险因素。血浆中循环的前蛋白转化酶枯草溶菌素9 (proprotein convertase subtilisin/kexin type 9, PCSK9)是一种肝细胞合成的丝氨酸蛋白酶,是低密度脂蛋白受体(low density lipoprotein receptor,LDLR)的关键调节因子,在控制血浆LDL-C水平方面发挥着关键作用,它通过与肝脏LDLR结合,形成PCSK9-LDLR复合物导致LDLR在溶酶体中降解,并减少肝细胞膜表面的LDLR的数量,进而导致血浆LDL-C水平升高。目前,临床常用他汀类降脂药物,如阿托伐他汀调节LDL-C水平,延缓AS,但药物起效慢,单一应用难以达到理想的效果,且会在不同程度上产生不良影响。因此, PCSK9是一种新的降低胆固醇的治疗靶点。本综述旨在阐明调控PCSK9的途径及改善AS的天然化合物的研究现状和潜在的治疗意义,以期为防治AS提供参考。展开更多
基金This work was partially supported by the National Natural Science Foundation of China （No. 30870870, WANG Shao-hua No. 30600206, GUO Yi-jing） and Natural Science Foundation of Jiangsu Province （No. BK2008302, WANG Shao-hua）.Acknowledgment： We would like to express our thanks to the nursing staff of the Division of Endocrinology, Zhongda Hospital of Southeast University, for their help.
文摘Background Dyslipidaemia is a potential independent The aim of this study was to investigate dyslipidaemia, with ischemic stroke in a Chinese hospital. risk factor for cerebrovascular disease in patients with diabetes. treatment and control of dyslipidaemia among diabetic patients Methods A total of 1046 type 2 diabetic patients were assigned to diabetes with （n=-522） and diabetes without stroke groups. The two groups were matched by gender, age and diabetes duration. Lipid and lipoprotein profile were measured. Serum level and control of lipids were assessed and classified according to American Diabetes Association （ADA） guidelines and an intensified low density lipoprotein-cholesterol （LDL-C） target recommended in Chinese dyslipidaemia control criteria. Results Diabetic patients suffering stroke displayed not only poorly-controlled lipid and lipoprotein profiles, including the significantly lower proportion of patients achieving intensified LDL-C target of 〈2.07 mmol/L （80 mg/dl）, and high density lipoprotein-cholesterol （HDL-C） target （14.4% vs 21.0%, P=0.005; 45.8% vs 51.9%, P=0.048 respectively）, but also less adherence to therapy prescribed for dyslipidaemia （30.8% vs 41.0%, P=0.001）, when compared with diabetic patients without stroke. For the diabetic women with stroke, situation of dyslipidaemia was worse, with significantly lower serum level of HDL-C and apoA1, higher LDL-C level and higher ratio of apoB/apoA1 when compared with diabetic counterparts without stroke. Conclusions Many diabetic patients with ischemic stroke remain uncontrolled for dyslipidaemia. Intensified LDL-C and overall lipid lowering clinical goals are potential precautions taken against ischemic stroke among diabetic patients in China.
文摘目的证实无论患者是否有血糖升高,非高密度脂蛋白胆固醇(non-high density lipoprotein-cholesterol,non-HDL-C)都是不弱于低密度脂蛋白胆固醇(low density lipoprotein-cholesterol,LDL-C)的评估血脂异常患者患者心血管病风险和降脂治疗疗效的有效临床指标。方法选取2007年首都医科大学附属北京同仁医院内分泌科大规模临床调查患者6 341例,检测总胆固醇(total cholesterol,TC)、高密度脂蛋白胆固醇(high density lipoprotein-cholesterol,LDL-C)、三酰甘油(triglyceride,TG),并且计算non-HDL-C(non-HDL-C等于TC-HDL-C)。根据空腹血糖高低分为血糖正常组和血糖升高组,比较两组中血脂异常患者的各项血脂指标;以non-HDL-C为纵轴,分别以LDL-C和TG为横轴作散点图。结果血糖升高组的TC、LDL-C、HDL-C、TG、non-HDL-C较血糖正常组均明显升高。作non-HDL-C与LDL-C和TG相关性的散点图并作趋势拟合线后,发现non-HDL-C与LDL-C、TG均呈线性正相关。结论 non-HDL-C是一项评估血脂异常患者心血管病风险和降脂治疗疗效的有效临床指标。
文摘目的评价血脂康胶囊治疗血脂异常的临床效果和安全性。方法计算机检索PubMed、Web of Science核心集、中国知网、万方、维普等数据库中血脂康治疗血脂异常随机对照试验,检索时间截至2018年6月。采用Revman5.3软件进行Meta分析,系统评价血脂康对总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)的影响。结果共纳入25项随机对照试验、7875例患者。Meta分析显示:与空白对照组比较,血脂康明显降低TC(WMD=-1.05,95%CI:-1.40,-0.70,P<0.01)和LDL-C(WMD=-0.76,95%CI:-0.94,-0.58,P<0.01)水平,升高LDL-C水平(WMD=0.17,95%CI:0.08,0.27,P<0.01)。与他汀对照组比较,血脂康能升高HDL-C水平(WMD=0.17,95%CI:0.04,0.30,P<0.05),虽然也降低TC和LDL-C水平,但差异无统计学意义(P>0.05)。与对照组比较,血脂康不良反应/主要心脑血管事件发生率明显降低(WMD=0.55,95%CI:0.47,0.64,P<0.01)。结论血脂康能够有效、全面地调脂,并且不良事件发生率低。
文摘Aim： To evaluate the impact of age and gender on lipid and lipoprotein profiles and the burden of dyslipidemia in a cohort of healthy Chinese Singaporean. Methods： A total of 1 775 healthy Chinese, 536 men and 1 239 women aged between 30 and 70 years old were involved in the present study. Results： Gender differences in all lipid and lipoprotein levels were clearly evident. Singaporean Chinese men have significantly higher levels of total cholesterol （TC）, triglyceride （TG）, low density lipoprotein-cholesterol （LDL-C） and total cholesterol/high density lipoprotein-cholesterol （TC/HDL-C）, and lower levels of HDL-C than women. Although lipid and lipoprotein levels in men did not change in the different age groups, those in women, especially TC, LDL-C and TC/HDL-C, were significantly higher in older women （〉 50 years old） than corresponding levels in younger women （30-46 years old）. Furthermore, TG was significantly correlated with lipids and lipoproteins differently in men and women. If 100 mg/dL of LDL-C were to be adopted as the therapeutic cut-off level, then the burden of care will be huge as approximately 90% of both Chinese men and women have LDL-C greater than 100 mg/dL. Condusion： In light of the findings of the present study, we suggest that preventive measures to promote the reduction in risk of coronary heart disease （CHD） must address the high proportion of men and women with high LDL-C, and that these measures should take into account both the gender and age factors. For men, reduction of high cholesterol must start early in life, whereas for women, steps must be taken earlier to mitigate the anticipated sharp increase in risk, especially after menopause.
文摘动脉粥样硬化(atherosclerosis, AS)是一种复杂的慢性进行性动脉疾病,被视为全球死亡的重要原因。高水平的血浆低密度脂蛋白胆固醇(low density lipoprotein-cholesterol, LDL-C)是AS发生和发展的关键危险因素。血浆中循环的前蛋白转化酶枯草溶菌素9 (proprotein convertase subtilisin/kexin type 9, PCSK9)是一种肝细胞合成的丝氨酸蛋白酶,是低密度脂蛋白受体(low density lipoprotein receptor,LDLR)的关键调节因子,在控制血浆LDL-C水平方面发挥着关键作用,它通过与肝脏LDLR结合,形成PCSK9-LDLR复合物导致LDLR在溶酶体中降解,并减少肝细胞膜表面的LDLR的数量,进而导致血浆LDL-C水平升高。目前,临床常用他汀类降脂药物,如阿托伐他汀调节LDL-C水平,延缓AS,但药物起效慢,单一应用难以达到理想的效果,且会在不同程度上产生不良影响。因此, PCSK9是一种新的降低胆固醇的治疗靶点。本综述旨在阐明调控PCSK9的途径及改善AS的天然化合物的研究现状和潜在的治疗意义,以期为防治AS提供参考。
